Related Experiment Videos
Decoy receptor 3 is highly expressed in patients with rheumatoid arthritis
Shinya Hayashi1, Yasushi Miura, Koji Tateishi
1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
Abstract:
Decoy receptor 3 (DcR3), a member of the tumor necrosis factor receptor (TNFR) superfamily, is a soluble receptor that binds to the TNF family including Fas ligand (Fas-L), LIGHT, and TL1A. DcR3 is mostly expressed in tumor cells and competitively inhibits the TNF family. We previously demonstrated that overexpressed DcR3 in rheumatoid synovial cells protects the cells from apoptosis in vitro. The objective of the study was to investigate DcR3 expression in serum and joint fluids of patients with rheumatoid arthritis (RA) and osteoarthritis (OA), and to analyze the correlations with disease activities and TNFalpha expression. Sera and joint fluids were collected from patients with RA and OA. Expression of DcR3 in sera and joint fluids was measured by ELISA. The concentration of DcR3 in sera and joint fluids of RA patients was significantly higher than that in sera and joint fluids of OA patients. A correlation between serum DcR3 concentration and disease activity was not observed, but the serum DcR3 concentration was strongly correlated with the TNFalpha concentration. DcR3 was highly expressed in serum and joint fluids of RA patients.
Insights
Decoy receptor 3 (DcR3) is highly expressed in rheumatoid arthritis (RA) patients. Higher DcR3 levels in RA serum correlate with TNFalpha, suggesting a role in RA pathogenesis.
Area of Science:
- Immunology
- Rheumatology
Background:
- Decoy receptor 3 (DcR3), a tumor necrosis factor receptor superfamily member, is a soluble receptor that inhibits TNF-family ligands.
- DcR3 is primarily expressed in tumor cells and has been shown to protect rheumatoid synovial cells from apoptosis in vitro.
Purpose of the Study:
- To investigate DcR3 expression in serum and joint fluids of patients with rheumatoid arthritis (RA) and osteoarthritis (OA).
- To analyze correlations between DcR3 levels, disease activity, and TNFalpha expression in RA and OA patients.
Main Methods:
- Sera and joint fluids were collected from RA and OA patients.
- DcR3 expression levels were quantified using ELISA.
- Correlations with disease activity and TNFalpha concentration were analyzed.
Main Results:
- DcR3 concentrations were significantly higher in serum and joint fluids of RA patients compared to OA patients.
- Serum DcR3 concentration showed a strong positive correlation with TNFalpha concentration.
- No significant correlation was observed between serum DcR3 concentration and RA disease activity.
Conclusions:
- DcR3 is highly expressed in the serum and joint fluids of RA patients.
- The strong correlation between DcR3 and TNFalpha suggests a potential role for DcR3 in RA pathogenesis.
- Further research is warranted to explore DcR3's specific contribution to RA inflammation and progression.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
The JAK-STAT Signaling Pathway
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Inflammatory Bowel Disease III: Crohn's Disease